![Graeme Fielder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graeme Fielder
Directeur des opérations chez AviadoBio Ltd.
Profil
Graeme Fielder is currently the Chief Operating Officer at AviadoBio Ltd.
He previously worked as the Head of Corporate Development at Astellas Gene Therapies, Inc. Dr. Fielder holds an MBA from Stanford University and has undergraduate and doctorate degrees from Auckland University.
Postes actifs de Graeme Fielder
Sociétés | Poste | Début |
---|---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Directeur des opérations | 04/10/2022 |
Anciens postes connus de Graeme Fielder
Sociétés | Poste | Fin |
---|---|---|
AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Graeme Fielder
Auckland University | Doctorate Degree |
Stanford University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
AviadoBio Ltd.
![]() AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Health Technology |
Astellas Gene Therapies, Inc.
![]() Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |